Lifecore Biomedical Acquired by Webster Equity Partners for Up to $663.7 Million
Lifecore Biomedical (NASDAQ: LFCR) has agreed to be acquired by private equity firm Webster Equity Partners in a deal valued at up to $663.7 million, contingent on the achievement of certain performance milestones. The transaction represents a significant strategic move for both parties and signals confidence in Lifecore’s growth potential. Lifecore is known for its expertise in manufacturing injectable drugs using lyophilization technology. Webster Equity Partners specializes in acquiring mid-market companies with strong operational foundations, suggesting the firm sees long-term value in expanding or enhancing Lifecore's capabilities post-acquisition.
Tickers: $LFCR
Topics: Lifecore Biomedical merger_and_acquisition Webster Equity Partners